|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,693.10 INR | -0.21% |
|
-1.40% | -1.55% |
| 10:04am | Organon Courted by Sun Pharmaceutical Industries, Grunenthal, Private Equity | MT |
| 04-14 | Sun Pharmaceutical Industries Enjoys Global Dose of Success |  |
| Capitalization | 4,071B 43.67B 36.99B 34.11B 32.17B 59.99B 60.96B 400B 157B 1,954B 164B 160B 6,939B | P/E ratio 2026 * |
34.9x | P/E ratio 2027 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise value | 3,847B 41.27B 34.96B 32.24B 30.4B 56.69B 57.61B 378B 148B 1,847B 155B 152B 6,557B | EV / Sales 2026 * |
6.62x | EV / Sales 2027 * | 5.83x |
| Free-Float |
44.9% | Yield 2026 * |
0.88% | Yield 2027 * | 0.98% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.21% | ||
| 1 week | -1.40% | ||
| Current month | -3.65% | ||
| 1 month | -5.05% | ||
| 3 months | +1.45% | ||
| 6 months | +2.06% | ||
| Current year | -1.55% |
| 1 week | 1,630.4 |  | 1,713.9 |
| 1 month | 1,620 | | 1,819 |
| Current year | 1,583.7 | | 1,843 |
| 1 year | 1,548 | | 1,851.2 |
| 3 years | 922.45 | | 1,960.35 |
| 5 years | 630.15 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 31/08/2025 | |
| Director of Finance/CFO | 58 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 24/05/2018 | |
| Director/Board Member | 70 | 20/05/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | -1.40% | 0.00% | +69.53% | 43.67B | |
| +1.52% | -2.06% | +58.08% | +143.30% | 35B | |
| +0.29% | +0.50% | -17.77% | +35.75% | 10.63B | |
| +8.15% | +4.65% | +89.49% | +79.87% | 11B | |
| +0.33% | +4.08% | +14.23% | +87.03% | 10.1B | |
| +0.62% | +2.75% | +42.23% | +118.47% | 8.71B | |
| +6.73% | +14.43% | +255.09% | +489.17% | 8.77B | |
| -0.90% | +2.74% | +22.74% | +60.45% | 7.57B | |
| +1.63% | -2.08% | +45.26% | -9.38% | 7.25B | |
| -0.39% | +3.71% | +65.79% | +358.80% | 6.84B | |
| Average | +1.78% | +2.23% | +57.51% | +143.30% | 14.95B | |
| Weighted average by Cap. | +1.38% | +0.39% | +43.64% | +122.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 581B 6.23B 5.28B 4.87B 4.59B 8.56B 8.7B 57.1B 22.35B 279B 23.39B 22.9B 990B | 648B 6.95B 5.88B 5.43B 5.12B 9.54B 9.7B 63.64B 24.91B 311B 26.06B 25.52B 1,104B |
| Net income | 115B 1.24B 1.05B 967M 912M 1.7B 1.73B 11.34B 4.44B 55.4B 4.64B 4.55B 197B | 135B 1.45B 1.23B 1.13B 1.07B 1.99B 2.02B 13.27B 5.19B 64.83B 5.44B 5.32B 230B |
| Net Debt | -224B -2.4B -2.04B -1.88B -1.77B -3.3B -3.35B -22.01B -8.61B -108B -9.01B -8.82B -382B | -298B -3.2B -2.71B -2.5B -2.36B -4.4B -4.47B -29.33B -11.48B -143B -12.01B -11.76B -509B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/04/26 | 1,693.10 ₹ | -0.21% | 4,512,633 |
| 15/04/26 | 1,696.60 ₹ | +2.69% | 3,760,449 |
| 13/04/26 | 1,652.20 ₹ | -0.16% | 3,751,005 |
| 10/04/26 | 1,654.90 ₹ | -3.62% | 8,089,531 |
| 09/04/26 | 1,717.10 ₹ | +0.15% | 3,276,165 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition